This week's biopharma funding and startup activity includes some significant milestones. Based in London, Myricx Bio closed £90M in Series A funding to advance its novel ADC payload platform. Kanvas Biosciences, from New Jersey, secured an additional $12.5M to progress its microbiome-based immuno-oncology pipeline.
Want to get this list of recently funded companies and more data? Fill out a quote request to get more info (Quote Request Form).
FIG. 1. Recent Biotech Funding Activity.
– Private Funding –
Myricx Bio
💸 Closed £90M Series A financing to develop their novel ADC payload platform.
Circle Pharma
💸 Sold $54.1M equity.
Kanvas Biosciences
💸 Secured an additional $12.5M to advance microbiome-based Immuno-oncology pipeline.
AnBogen
💸 Completed $7.3M oversubscribed Series A+ financing led by KGI Venture Capital to further ABT-301 Ph2 trials.
Granza Bio
💸 Raised $7.14M seed round led by Felicis and Refactor, with participation from Y Combinator to advance oncology and autoimmune treatment.
– Post-IPO/Public Funding –
Cartesian Therapeutics
🏦 Secured $130M in financing for its pipeline programs and general corporate purposes.
BioNano Genomics
🏦 Announced a $30M public offering with $10M upfront and an additional $20M upon exercise of clinical milestone-linked warrants
e-Therapeutics
🏦 Completed £28.9M fundraising to advance multiple GalOmic™ pipeline assets.
InspireMD
🏦 Announced full exercise of $17.9M Series H warrants following positive outcomes result from C-GUARDIAN trial.
Checkpoint Therapeutics
🏦 Raised $12M in a direct offering for working capital and corporate purposes.
---
Article History:
RF, DV, DG (07/09/24)
This article is not investment or legal advice.
Comments